RT Journal Article
T1 Mast cell-mediated splanchnic cholestatic inflammation
A1 Aller Reyero, María De Los-Ángeles
A1 Martínez, Vicente
A1 Arias, Ana
A1 Nava, María Paz
A1 Cuervas-Mons, Valentín
A1 Vergara, Patri
A1 Arias Pérez, Jaime
AB IntroductionSplanchnic mast cells increase in chronic liver and in acute-on-chronic liver diseases. We administered Ketotifen, a mast cell stabilizer, and measured the mast cells in the splanchnic organs of cholestatic rats.Material and MethodsThese groups were studied: sham-operated rats (S; n = 15), untreated microsurgical cholestasic rats (C; n = 20) and rats treated with Ketotifen: early (SK-e; n = 20 and CKe; n = 18), and late (SK-l; n = 15 and CK-l; n = 14).ResultsThe cholestatic rats showed systemic and splanchnic impairments, such as ascites, portal hypertension, and biliary proliferation and fibrosis. The rats also showed a splanchnic increase of TNF-α, IL-1β and MCP-1, and a reduction of IL-4, IL-10 and antioxidants. An increase of VEGF in the ileum and mesenteric lymphatic complex was associated with a liver reduction of TGF-β1. Ketotifen reduces the degree of hepatic insufficiency and the splanchnic inflammatory mediators, as well as VEGF and TGF-ß1 levels. Ketotifen also reduces the connective tissue mast cells in the mesenteric lymphatic complex of cholestatic rats, while increases the hepatic mucosal mast cells.ConclusionsIn cholestatic rats, Ketotifen improves liver function and ascites, and also reduces pro-inflammatory mediators in the splanchnic area. The decrease in connective tissue mast cells in the mesenteric lymphatic complex due to the administration of Ketotifen would lead to the improvement of the inflammatory splanchnic response, and consequently the abovementioned complications.
PB Elsevier
SN 2210-741X
YR 2019
FD 2019-03-08
LK https://hdl.handle.net/20.500.14352/13608
UL https://hdl.handle.net/20.500.14352/13608
LA eng
NO Mutua Madrileña Automovilista
DS Docta Complutense
RD 9 jul 2025